Zacks Industry Outlook Highlights: Medtronic, Boston Scientific, St. Jude Medical, Edwards Lifesciences & Varian Medical - Pr..
March 07 2012 - 3:30AM
Zacks
For Immediate Release
Chicago, IL – March 7, 2012 – Today, Zacks Equity Research
discusses the MedTech Industry, including Medtronic
Inc. ( MDT), Boston Scientific
Corporation ( BSX), St. Jude
Medical ( STJ), Edwards
Lifesciences ( EW) and Varian
Medical ( VAR).
A synopsis of today’s Industry Outlook is presented below. The
full article can be read at
http://www.zacks.com/stock/news/70847/MedTech+Industry+Stock+Outlook+%96+March+2012
In our universe, we see growth potential in companies dealing
with cardiovascular devices, neuro and radiation oncology products.
Names include Medtronic Inc. (
MDT), Boston Scientific Corporation (
BSX), St. Jude Medical (
STJ), Edwards Lifesciences ( EW)
and Varian Medical ( VAR).
The above-listed companies make life-sustaining products and are
less affected by economic instability. These companies are all
leading players in their respective fields and are potential
winners in the long run. Some of these players have been successful
in weathering the storm (pricing, currency and volume headwinds) in
the cardiovascular space.
With a slew of new products, the Big Three players (Medtronic,
Boston Scientific and St. Jude) in the $6.5 billion implantable
cardioverter defibrillator (“ICD”) market are well-positioned to
gain market share, despite the challenging business environment and
several other barriers to growth. These companies have a number of
levers to pull and represent a good bet for long-term
investors.
Among the names above, Medtronic, the undisputed leader in the
MedTech space, has a diversified presence in cardiovascular, neuro,
spinal, diabetes and ENT and boasts of an attractive pipeline.
Despite sustained weaknesses in its key ICD and spinal implants
businesses, we like the company’s efforts to augment/diversify its
product range, expand into emerging markets for growth, and
generate strong cash and healthy dividend yield. Besides, the new
MRI SureScan pacemaker and Protects ICDs should offer support to
its core CRM business.
Boston Scientific has maintained its leadership in the drug eluting
stent (“DES”) market. The earlier-than-expected approval of the
next-generation DES product Promus Element coupled with a new line
of ICDs better places the company for 2012. Although Boston
Scientific’s December quarter results were disappointing and its
CRM segment remains challenging, we believe that the company’s
continuous focus on strategic initiatives (including new products
and cost cutting measures) to drive growth and profitability should
yield steady results moving ahead.
Boston Scientific is leaving no stone unturned to stay on course
for growth. It has undertaken a series of management changes and
restructuring initiatives that are expected to contribute to the
bottom line and margins. The company is also expanding its
footprint in the emerging markets by reinvesting the savings from
restructuring efforts.
We remain intrigued by St. Jude’s ability to consistently produce
positive earnings surprises and revenue growth. The company is
gaining ICD market share despite a sluggish market condition. St.
Jude is poised for incremental opportunities in CRM on the back of
strong product momentum. A surfeit of new growth drivers are
expected to offer opportunities for accelerated sales growth over
the next few years.
St. Jude recently won the U.S. approval for its Unify quadripolar
CRT-D system. The device is expected to help the company win ground
in the highly competitive U.S. defibrillator space in 2012. St.
Jude is currently the only company to offer this technology
globally. Moreover, St. Jude is well placed to leverage the solid
growth momentum in the atrial fibrillation market.
Zacks "Profit from the Pros" e-mail newsletter provides
highlights of the latest analysis from Zacks Equity Research.
Subscribe to this free newsletter today by visiting
http://at.zacks.com/?id=2679.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc.,
which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len
knew he could find patterns in stock market data that would lead to
superior investment results. Amongst his many accomplishments was
the formation of his proprietary stock picking system; the Zacks
Rank, which continues to outperform the market by nearly a 3 to 1
margin. The best way to unlock the profitable stock recommendations
and market insights of Zacks Investment
Research is through our free daily email newsletter; Profit from
the Pros. In short, it's your steady flow of Profitable ideas
GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at
http://at.zacks.com/?id=4581.
Visit http://www.zacks.com/performance for information about the
performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook:
http://www.facebook.com/ZacksInvestmentResearch
Disclaimer: Past performance does not guarantee future results.
Investors should always research companies and securities before
making any investments. Nothing herein should be construed as an
offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
EDWARDS LIFESCI (EW): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
VARIAN MEDICAL (VAR): Free Stock Analysis Report
To read this article on Zacks.com click here.
SJM (NYSE:STJ)
Historical Stock Chart
From May 2024 to Jun 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2023 to Jun 2024